Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)

Next Previous
Trial Profile

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bavunalimab (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Carcinoma; Cervical cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Liver cancer; Male breast cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Penile cancer; Peritoneal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer; Uveal melanoma
  • Focus Adverse reactions
  • Acronyms DUET-4
  • Sponsors Xencor

Most Recent Events

  • 29 Mar 2023 Status changed from active, no longer recruiting to completed.
  • 27 May 2022 Status changed from recruiting to active, no longer recruiting.
  • 03 May 2021 Planned End Date changed from 1 Mar 2027 to 1 Nov 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top